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Abstract
Ribosomes are abundant, large RNA–protein complexes that are the source of all protein synthesis in the
cell. The production of ribosomes is an extremely energetically expensive cellular process that has long
been linked to human health and disease. More recently, it has been shown that ribosome biogenesis is
intimately linked to multiple cellular signalling pathways and that defects in ribosome production can lead
to a wide variety of human diseases. Furthermore, changes in ribosome production in response to nutrient
levels in the diet lead to metabolic re-programming of the liver. Reduced or abnormal ribosome production
in response to cellular stress or mutations in genes encoding factors critical for ribosome biogenesis causes
the activation of the tumour suppressor p53, which leads to re-programming of cellular transcription. The
ribosomal assembly intermediate 5S RNP (ribonucleoprotein particle), containing RPL5, RPL11 and the 5S
rRNA, accumulates when ribosome biogenesis is blocked. The excess 5S RNP binds to murine double minute
2 (MDM2), the main p53-suppressor in the cell, inhibiting its function and leading to p53 activation. Here,
we discuss the involvement of ribosome biogenesis in the homoeostasis of p53 in the cell and in human
health and disease.
Ribosome production
The ribosome is a large RNA–protein machine that
synthesizes all cellular proteins. Ribosomes consist of two
subunits: the small [small ribosomal subunit (SSU); 18S
rRNA and 33 ribosomal proteins (RPs)] and large [large
ribosomal subunit (LSU); the 28S, 5.8S and 5S rRNAs and 46
RPs] ribosomal subunits [1]. The 28S (25S in yeast), 18S and
5.8S rRNAs are co-transcribed by RNA polymerase I as part
of a long single precursor (47S or 35S pre-rRNA in yeast).
Ribosomes are assembled on the 47 S precursor transcript as
it undergoes multiple processing and modification steps [1]
(Figure 1A). RNA polymerase I transcription appears rate-
limiting for ribosome production, whereas RPs are produced
in significant excess with the unused proteins being rapidly
degraded by the proteasome [2]. In contrast, the 5S rRNA
is transcribed by RNA polymerase III and is incorporated
into the 5S RNP (ribonucleoprotein particle), a ribosome
assembly intermediate that also contains the RPs RPL5 and
RPL11, before being integrated into the ribosome. Most of
the steps of ribosome production occur in the nucleolus, a
sub-compartment of the nucleus, with later steps taking place
in the nucleoplasm and the cytoplasm [1] (Figure 1A).
Ribosome biogenesis is the major consumer of cellular
energy that is up-regulated in cancer, with changes in
nucleolar morphology being a hallmark of transformed cells,
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and down-regulated during cell division and differentiation
[3]. Furthermore, ribosome biogenesis is affected by many, if
not all, forms of cellular stress including DNA damage, on-
cogene overexpression (oncogenic stress), hypoxia, oxidative
stress and nutritional stress [4]. Not surprisingly, ribosome
production is also regulated by oncogenes such as c-myc and
tumour suppressors such as p53, retinoblastoma protein (Rb)
and p14ARF [4]. More recently, it has emerged that ribosome
biogenesis also controls multiple cellular signalling pathways
and defects in this process can lead to disease.
The 5S RNP controls the tumour suppressor
p53 through MDM2
The tumour suppressor p53 is controlled by the E3 ubiquitin
ligase murine double minute 2 (MDM2). Together with the
related protein MDMX (also known as MDM4), MDM2
binds to p53, blocking the transcriptional activity of p53 and
leading to its ubiquitylation, which targets it for proteosomal
degradation [5] (Figure 1B).Anumber ofRPs of both the SSU
(RPS3, RPS7, RPS14, RPS15, RPS20, RPS25, RPS26, RPS27,
RPS27L and RPS27a) and LSU (RPL4, RPL5, RPL6, RPL11,
RPL23,RPL26 andRPL37) has been shown tobind andblock
the activity of MDM2 [6,7]. The initial model proposed that
disruption of ribosome biogenesis leads to the accumulation
of free RPs, which bind MDM2 and activate p53 [6]. One
problemwith thismodel is that almost all RPs are synthesized
in excess and free proteins are rapidly degraded making it
difficult to see how they would be stable enough to interact
withMDM2 [2]. Moreover, only in the case of RPL5, RPL11,
RPL23, RPS3 andRPS27a have the endogenous proteins been
shown to bind MDM2 in vivo [8–11]. Furthermore, of all
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Figure 1 Ribosome biogenesis and p53 signalling
(A) Schematic representation of ribosome biogenesis and the link between the 5S RNP and MDM2. Three of the rRNAs (18S,
5.8S and 28S) are transcribed by RNA polymerase I (Pol I) in the nucleolus, whereas the 5S rRNA is transcribed by RNA
polymerase III (Pol III) in the nucleoplasm. The mature (18S, 5.8S, 28S and 5S) rRNAs and the precursor rRNAs (47S, 21S,
18SE, 32S and 7S) are indicated. The LSU ribosome biogenesis factors PAK1IP1 and PICT1 are shown. (B) Illustration of the
5S RNP interaction with MDM2 and the regulation of p53 signalling in both unstressed and stressed cells; Ub: ubiquitin.
the RPs tested, only RPL5, RPL11 and RPS27a have been
demonstrated to be essential for p53 activation in response to
defects in ribosome biogenesis [8,10,12–14].
Overexpression of the RPs was predicted to result in p53
activation suggesting a role in p53 regulation [6,7]. It was
recently shown that RPL4 overexpression activates p53 in
an RPL5 and RPL11-dependent manner [7]. One possible
explanation for this p53 activation is that overexpression
of single RPs could imbalance RP production causing
overproduction of the 5S RNP. Although the data on RPL5-
and RPL11-mediated regulation of MDM2 are now clear,
clarification about which other RPs naturally bind MDM2
and regulate p53 in response to defects in ribosome biogenesis
is clearly needed.
RPL5 and RPL11, together with the 5S rRNA, form
the 5S RNP, a stable assembly intermediate of the LSU
(Figure 1A). Previous data indicate that the 5S RNP, and not
the individual RPs RPL5 and RPL11, binds and regulates
MDM2 in unstressed cells [8,12,14]. This interaction is
enhanced after defects in ribosome production when the
5S RNP accumulates [14]. All three components of the
5S RNP contact MDM2 [14–18] and all three are needed
for p53 activation in response to defects in ribosome
biogenesis [12,14]. The 5S RNP–MDM2 pathway is needed
for activation of p53 by chemotherapeutic drugs (e.g.
actinomycin D and 5-fluorouracil), low nucleotide levels in
the cell, nutrient starvation and overexpression of the tumour
suppressor p14ARF [12,14,19–21]. Ribosome biogenesis
and the 5S RNP–MDM2 pathway are also thought to be
important for the unfolded protein response [22] and likely to
be involved in the response to many forms of stress including
hypoxia and oxidative stress. Indeed, only p53 activation by
DNA damage has been shown to occur independently of
the 5S RNP–MDM2 interaction [23], indicating that the 5S
RNP–MDM2 pathway is a major p53 regulatory mechanism
in the cell.
The cell contains a large amount of the RPL5/5S rRNA
complex, an intermediate in 5S RNP formation (Figure 1A),
and the recruitment ofRPL11 to theRPL5/5S rRNAcomplex
to form the 5S RNP is rate-limiting [14]. Since individual,
unbound RPs are unstable, the 5S RNP complex provides
a means by which RPL5 and RPL11 can accumulate when
ribosome production is blocked [8,14]. Monitoring the levels
of the 5S RNP, which is only present at low levels normally
in the cell, therefore provides a good measure of the rate
and integrity of ribosome production especially since the
mature subunits are very long-lived with estimated half-lives
of 5 days in rat livers [24]. Unexpectedly, defects in SSU
production also lead to 5S RNP-mediated activation of p53 in
the absence of noticeable changes in LSU production. In this
instance, reduction in SSU levels is predicted to lead to the
up-regulation of RP production and the increased production
of the 5S RNP [13].
Recent structural work has shown that the binding of
the 5S RNP to MDM2 and to the ribosome are mutually
exclusive events [25]. The same binding site in RPL11 is used
in both cases (Figure 2) thus preventing the interaction of the
ribosome-bound 5SRNPwithMDM2.Anumber of proteins
have been linked to the regulation of p53 by the 5S RNP
and ribosome production, including the essential ribosome
biogenesis factors PAK1IP1 (Mak11 in yeast) and PICT1
(also known as GLTSCR2 and Nop53 in yeast), which are
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Figure 2 The interaction of MDM2 and the ribosome with the 5S
RNP is mutually exclusive
Structure of the human 5S RNP bound to (A) nucleotides 4237–4288 of
the 28S rRNA [51] and (B) a fragment of MDM2 including the zinc finger
[25]. Surface and cartoon views of the RPs and rRNAs respectively, are
shown. Images were generated using PyMOL software.
essential for theproductionof theLSU(Figure 1A) [14,26,27].
These proteins, like all ribosome biogenesis factors, are
involved in p53 regulation by performing their basic function
in ribosome production.
MDM2 regulates a number of signalling factors in the cell
including the p53-related proteins p63 and p73 [28]. It is
therefore likely that the 5S RNP regulates multiple cellular
signalling pathways through its interaction with MDM2.
Recently, RPL5 and RPL11, presumably as part of the 5S
RNP, were shown to regulate p73 [29]. However, instead
of binding to, and blocking MDM2 activity, RPL5 and
RPL11 directly bind to p73 and block the interaction of
p73 with the suppressor MDM2. Furthermore, RPL11 has
also been shown to bind and suppress the transcriptional
activity of the proto-oncogene c-myc in response to defects
in ribosome biogenesis [30]. In addition, RPL5 and RPL11
co-operatively recruit the RNA-induced silencing complex
to degrade the c-myc mRNA [30]. It is likely that both the
regulation of c-myc activity and c-myc mRNA stability are
regulated by the 5S RNP. It will be interesting to see what
other signalling pathways are regulated through the 5S RNP
complex.
The importance of ribosome biogenesis in
human health and disease
Changes in ribosome biogenesis have been linked to a
wide range of conditions including cardiovascular, neuro-
degenerative and skeletal disorders as well as cancer [31–
34]. An ever-growing number of rare genetic diseases,
termed ribosomopathies, have been attributed to defects
in ribosome production [35,36]. These diseases arise due
to mutations in genes encoding RPs or proteins important
for ribosome production. Common clinical manifestations
include macrocytic anaemia, skeletal defects, skin problems
and, notably, a pre-disposition to cancer. In many cases,
p53 levels have been shown to be de-regulated and, in
some animal models, the clinical symptoms of the diseases
have been shown to be p53-dependent. Evidence suggests
that defects in ribosome production in these cases lead
to 5S RNP accumulation and subsequent p53 activation.
The most-studied ribosomopathies are Diamond–Blackfan
anaemia (DBA), Shwachman–Diamond syndrome (SDS), 5q
syndrome and Treacher Collins syndrome (TCS). Where
the mutant gene has been identified, the majority of DBA
patients have mutations in genes encoding RPs including
RPS19, RPS24, RPS17, RPS7, RPL35A, RPL5 and RPL11,
and defects in pre-rRNA processing are commonly used
as a diagnostic tool for this disease [37]. DBA patients
present with hypoplastic macrocytic anaemia together with
heterogeneous anomalies including skeletal, urogenital and
cardiac defects. In DBA animal models some, but not all of
the symptoms have been shown to be p53-dependent and
the anaemia is dependent on the interaction between the 5S
RNP and MDM2 [38]. Like DBA, 5q syndrome presents
with macrocytic anaemia and is a form of myelodysplastic
syndrome (MDS) [39]. 5q syndrome is caused by deletion
of chromosome 5q, which contains the gene encoding
RPS14. The anaemia in 5q syndrome has been attributed to
haploinsufficiency of RPS14 and is p53-dependent in mouse
models [40]. SDS is caused by mutations in the SBDS gene,
which encodes a protein important for the late, cytoplasmic
stages of LSU maturation [41]. SDS patients present with
endocrine pancreatic insufficiency, ineffective haematopoiesis
and, occasionally, anaemia and skeletal defects. Mutations in
TCOF1, and less commonly the RNA polymerase I and III
subunits POLR1C and POLR1D, cause TCS. TCOF1 is
important for both the transcription and 2′-O-methylation
of the rRNA [34]. TCS presents with craniofacial anomalies
due to proliferation defects of neural crest cells during early
development. A mouse model successfully replicated the
clinical phenotype bymutating the TCOF1 gene, and further
work revealed the craniofacial defects to be p53-dependent
[42].
For some time now, ribosome biogenesis has been known
to be linked to cancer. Changes in nucleolar structure (as seen
byAgNORstaining) and an increase in ribosome production
are two hallmarks of cellular transformation [4]. Strikingly,
many anti-cancer chemotherapeutics, including actinomycin
D and 5-fluorouracil, block ribosome biogenesis [43] making
it a promising target for new cancer therapies [44]. The
tumour suppressor p14ARF, which needs the 5S RNP for
its full capability to activate p53 [14], is also a suppressor
of ribosome production [45]. However, the most striking
link is seen with the highly abundant nucleolar protein
nucleophosmin (NPM1), which is mutated in approximately
30%of leukaemias [46].More recently, exome sequencinghas
revealed mutations in RPL5, RPL10, RPL11, RPL22, RPS15
andRPS20 in a variety of cancers butmost notably leukaemias
[47]. In particular, RPS15 mutations are associated with an
aggressive, relapsed form of chronic lymphocytic leukaemia
(CLL) and frequently found associated with mutations in
the p53 gene [48]. In many ribosomopathies, the patients are
pre-disposed to multiple forms of cancer. For example DBA
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence
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patients have a 5-fold higher risk of cancer than the general
population with a 28- to 36-fold higher incidence of acute
myeloid leukaemia (AML), osteosarcoma or colon cancer
[47]. AML is the most common form of cancer associated
with ribosomopathy patients. Solid tumours, such as head
and neck tumours or osteosarcomas, are less common but
also seen [49]. The increase in cancer rate in ribosomopathy
patients appears counter-intuitive since theyoftenhavehigher
than normal levels of p53. However, it could be that the
patient’s cells become desensitized to p53 or that there is
pressure to mutate or affect the p53 pathway when p53 levels
are elevated.
Recent work has indicated a role for p53 in the regulation
of cellular metabolism. This was highlighted in a mouse
model carrying a cancer derived point mutation, C305F,
in MDM2 [20]. This mutation blocks the 5S RNP–MDM2
interaction and renders the mouse cells insensitive to p53
activation when ribosome biogenesis is blocked using low
levels of actinomycin D [23]. In addition, this mutation
also increases the rate the mice develop c-myc-induced
lymphomas. Interestingly, the MDM2–C305F mutation
promotes fat accumulation in mice under normal conditions
and hepatosteatosis under fasting conditions [20]. It was
further shown that ribosome biogenesis, and the 5S RNP–
MDM2 pathway, is the sensor responsible for p53-mediated
remodelling of lipid homoeostasis in the liver in response
to restricted nutrients. In a separate study, it was found
that the protein nucleomethylin (NML) functions to repress
rRNA transcription in the livers of mice fed a high-fat diet
[50]. NML-null mice showed a reduced lipid accumulation
in the liver and these mice did not become obese on a
sustained high-fat diet. It is unclear whether NML-mediated
suppression of rRNA transcription functions to control
liver metabolism through p53, although it is likely that
the livers in mice fed with a high-fat diet contain elevated
levels of p53. It is therefore clear that the regulation of
ribosome production is a major nutrient sensor and critical
for the correct response to changes in diet that affect liver
function.
Concluding remarks
Research in the last few years has revealed how intimately
ribosome biogenesis is linked to cellular signalling and, in
particular, to the control of the tumour suppressor p53.
It is now clear that cellular signalling depends on the
levels of a ribosome assembly intermediate, the 5S RNP,
which together with MDM2, plays a pivotal role in this
pathway. This is linked to the basic tumour suppressor/anti-
proliferation aspect of p53 andhigh levels of the 5SRNPcause
p53-dependent cell cycle arrest, apoptosis or senescence.
However, intriguingly, the 5S RNP/MDM2 pathway also
appears to regulate lipid metabolism in the liver in response
to changes in diet. Furthermore, the 5S RNP is also linked to
the control of other signalling factors such as c-myc and p73.
Indeed, it is likely that, in the coming years, the 5S RNP will
be revealed to be a central hub regulating multiple aspects of
cellular signalling.
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